WANG JEFF

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

Mullerian Inhibiting Substance analogues are disclosed which comprise one or more non-naturally occurring N-linked glycosylation sites, protease cleavage sites, and/or tags such as an epitope tag. Also disclosed are pharmaceutical compositi…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…

We have discovered that Müllerian Inhibiting Substance (MIS) can be used therapeutically to treat or prevent endometriosis in mammals, particularly humans. In a preferred embodiment a therapeutically effective amount of human MIS or a biolo…